Provided by Tiger Trade Technology Pte. Ltd.

Compugen

1.68
+0.03001.82%
Post-market: 1.700.0200+1.19%16:51 EST
Volume:132.89K
Turnover:222.56K
Market Cap:157.14M
PE:-5.59
High:1.71
Open:1.65
Low:1.63
Close:1.65
52wk High:2.38
52wk Low:1.13
Shares:93.54M
Float Shares:91.62M
Volume Ratio:0.70
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3005
EPS(LYR):-0.1600
ROE:-52.95%
ROA:-18.18%
PB:3.59
PE(LYR):-10.50

Loading ...

Compugen Ltd. to Release Fourth Quarter and Full Year Results

Reuters
·
Yesterday

Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors

Reuters
·
Feb 12

Compugen Appoints Michele Holcomb to Board of Directors

Reuters
·
Feb 12

Press Release: Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Dow Jones
·
Feb 12

HC Wainwright Initiates Compugen at Buy With $4 Price Target

MT Newswires Live
·
Jan 07

Compugen Shares Rise On Monetization of Cancer Drug Royalties to AstraZeneca

Dow Jones
·
Dec 17, 2025

Compugen Sells Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Reuters
·
Dec 17, 2025

Compugen’s Earnings Call: Strategic Focus Amid Financial Challenges

TIPRANKS
·
Nov 11, 2025

Clinical-stage cancer immunotherapy firm Compugen's Q3 net loss widens

Reuters
·
Nov 10, 2025

Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million

Reuters
·
Nov 10, 2025

Compugen Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $1.891M Beat $1.469M Estimate

Benzinga
·
Nov 10, 2025

Press Release: Compugen Reports Third Quarter 2025 Results

Dow Jones
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Compugen Ltd. to Join Stifel 2025 Healthcare Conference

Reuters
·
Nov 04, 2025

Compugen Announces Interim Analysis Timeline for MAIA-Ovarian Trial of COM701 as Maintenance Therapy in Platinum-Sensitive Ovarian Cancer

Reuters
·
Oct 13, 2025

Compugen Ltd. Announces First-in-Human Clinical Trial of Anti-IL18BP Antibody COM503 in Advanced Solid Tumors at SITC 2025

Reuters
·
Oct 06, 2025

Compugen’s Shareholders Approve All Proposals at 2025 Annual Meeting

TIPRANKS
·
Sep 17, 2025